Medical Condition

neuroblastoma

Total Trials

12

Recruiting Now

12

Trial Phases

Phase 1, Phase 2, EARLY_Phase 1, Phase 1

ClinicalMetric tracks all active clinical trials for neuroblastoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — neuroblastoma Clinical Trials

How many clinical trials are currently recruiting for neuroblastoma?

ClinicalMetric currently tracks 12 actively recruiting clinical trials for neuroblastoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 12. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for neuroblastoma?

neuroblastoma research spans Phase 1 (7 trials), Phase 2 (4 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a neuroblastoma clinical trial?

Eligibility criteria for neuroblastoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

Princess Maxima Center for Pediatric Oncology 1 trial

Sichuan University 1 trial

Baylor College of Medicine 1 trial

Brigham and Women's Hospital 1 trial

Nationwide Children's Hospital 1 trial

Recruiting Clinical Trials

NCT07399821 Phase 1, Phase 2

Recruiting

An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma

Princess Maxima Center for Ped...

View Trial →

NCT07067346 EARLY_Phase 1

Recruiting

Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma

GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma

Baylor College of Medicine

View Trial →

NCT06000787

Recruiting

MCT for the Harvard/UCSF ROBIN Center

Brigham and Women's Hospital

View Trial →

NCT05135975 Phase 2

Recruiting

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Nationwide Children's Hospital

View Trial →

NCT04851119 Phase 1, Phase 2

Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

View Trial →

NCT05890781

Recruiting

Engineering Immune Organoids to Study Pediatric Cancer

Gustave Roussy, Cancer Campus,...

View Trial →

NCT04897321 Phase 1

Recruiting

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

St. Jude Children's Research H...

View Trial →

NCT06395103 Phase 1, Phase 2

Recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Enrollment

90 pts

Location

United States, Austr...

Sponsor

Merck Sharp & Dohme LLC

View Trial →

NCT05400603 Phase 1

Recruiting

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma

Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma

Federal Research Institute of ...

View Trial →

NCT06574698

Recruiting

Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

Guangzhou Women and Children's...

View Trial →

Related Conditions

sarcoma (2) melanoma (2) refractory osteosarcoma (2) wilms tumor (2) ewing sarcoma (2) glioma childhood brainstem (1) colorectal carcinoma (1) endometrial carcinoma (1) ovarian carcinoma (1) pancreatic ductal adenocarcinoma (1) recurrent desmoid fibromatosis (1) recurrent ewing sarcoma (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology